SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.

Journal: Open forum infectious diseases
Published Date: Nov 23, 2021

Abstract

BACKGROUND: Itraconazole (ITZ) is an effective agent when used as primary invasive fungal disease (IFD) prophylaxis, but is limited by drug tolerability and variability in serum concentrations. A new formulation, SUBA-itraconazole (for "super bioavailability"; S-ITZ), addresses the limitations of conventional ITZ formulations.

Authors

  • Julian Lindsay
    National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Jad Othman
    Haematology Department, Royal North Shore Hospital, Sydney, Australia.
  • Yvonne Kong
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.
  • Annie Yip
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.
  • Sebastiaan Van Hal
    Infectious Diseases Department, Royal Prince Alfred Hospital, Sydney, Australia.
  • Stephen Larsen
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.
  • Christian Bryant
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.
  • John Gibson
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.
  • Ian Kerridge
    Haematology Department, Royal North Shore Hospital, Sydney, Australia.
  • Keith Fay
    Haematology Department, Royal North Shore Hospital, Sydney, Australia.
  • William Stevenson
    Haematology Department, Royal North Shore Hospital, Sydney, Australia.
  • Chris Arthur
    Haematology Department, Royal North Shore Hospital, Sydney, Australia.
  • Sharon C A Chen
    National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • David C M Kong
    National Health and Medical Research Council National Centre for Antimicrobial Stewardship at the Peter Doherty Institute for Infections and Immunity, Parkville, Victoria, Australia.
  • Matthew Greenwood
    Haematology Department, Royal North Shore Hospital, Sydney, Australia.
  • Steven A Pergam
    Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Catherine Liu
    Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Monica A Slavin
    National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals